Pramipexole may slow progress of Parkinson’s disease
in early stage
RESULTS of an in vitro study have indicated
that pramipexole (Mirapexin) reduces the cell death and loss of mitochondrial
function induced by methylphenylpyridinium ions (MPP+). This suggests
that the drug could slow the progression of Parkinson’s disease, say researchers
from London.
Methylphenylpyridinium ions are known to induce
Parkinson’s disease, said Dr Anthony Schapira from the Royal Free and
University College Medical School, who presented the findings at the American
Academy of Neurology in Philadelphia, last month.
Pramipexole significantly decreased the effects
of MPP+ on cell death and on the mitochondria — generally by about 50
per cent, he said. Dr Schapira added that if the drug were shown to be
protective in vivo, then he would expect it to be prescribed as
early as possible in the course of the disease.
Back to Top
|
